
We envision a world where
DISEASES DRIVEN BY
INFLAMMATION
are treatable at their source


With an advanced suite of tools in our arsenal, a deep pipeline and an unparalleled team of experts guiding our approach, NodThera is leading the charge in targeting the NLRP3 inflammasome to usher in a new era of anti-inflammatory therapeutics
Alan Watt, PhD, MBA
Chief Executive Officer
Meet the experts
The NodThera team is led by masters of their craft – industry leaders with the right mix of creativity, imagination, skill and expertise that will bring the potential of NLRP3-targeting medicines to life.
To unlock the potential of NLRP3 inflammasome inhibition means we will be able to deliver viable medicines to millions of patients suffering from chronic inflammatory diseases.

Cardiovascular Disease

Osteoarthritis

Neuroinflammation
